ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0721

Does Serial ANCA Testing Help Predict the Risk of Relapse in Granulomatosis with Polyangiitis? A Single-center Cohort Study

Xavier Puéchal1, Michele Iudici1, Elodie Perrodeau2, Claire Goulvestre3, Pascal cohen4, Alexis Régent1, Luc Mouthon5, Loïc Guillevin4, Raphael Porcher6 and Benjamin Terrier7, 1National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, 2Hôtel-Dieu, Paris, France, 3Laboratoire d'immunologie, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, 4National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, 5Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 6Department of Rheumatology, Bicêtre AP-HP Hôpital, Université Paris-Saclay, Paris, Ile-de-France, France, 7Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France

Meeting: ACR Convergence 2024

Keywords: ANCA, Granulomatosis with Polyangiitis (GPA), Measurement, Outcome measures, risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Vasculitis – ANCA-Associated Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: ANCA-associated vasculitis (AAV) is a frequently relapsing disease for which a meta-analysis concluded that an increase or persistence of ANCA during remission is only moderately predictive of future disease relapse and that serial ANCA measurements during remission are of limited use in guiding treatment decisions for individual patients. However, this analysis analyzed heterogeneous ANCA assays and combined different subgroups of AAV patients or PR3 and MPO-AAV patients, whereas granulomatosis with polyangiitis (GPA) and PR3-AAV have a higher relapse risk. We investigated whether serial ANCA testing with a uniform ELISA assay could be of interest in predicting relapse risk in a cohort of GPA patients.

Methods: To be included, patients had to have GPA follow-up at our National Referral Center, at least two measurements of ANCA titer by ELISA less than 12 months apart during inactive disease, and an assessment of disease activity within 18 months of the second ANCA titer measurement. The primary objective was to evaluate the association of an increase in ANCA titer at the time of inactive disease with any relapse. The primary endpoint was the cumulative incidence of relapse within the following 18 months. To obtain confounder-adjusted relapse-free survival curves for each group, we used direct standardization (G-computation) using a Cox regression model. The results were analyzed globally in time periods where patients had an increased ANCA titer (Increase group) compared to those without (No increase group) and in a subgroup of PR3-AAV patients. We also estimated 18-month adjusted restricted mean survival times (RMST). In a sensitivity analysis, we compared patients with ANCA doubling versus no doubling.

Results: 125 GPA patients were analyzed in the primary analysis (PR3-ANCA: 105; MPO-ANCA: 20) for a total of 378 patient-periods. We observed 74 relapses, 7 out of 23 patient-periods in the Increase group (unadjusted relapse rate: 33.8%) vs. 67 out of 355 patient-periods in the No increase group (unadjusted relapse rate: 25.5%). Of the 23 periods of increased ANCA levels, 16 were not followed by a relapse. The adjusted relapse rates were 31.0% (11.2−54.4) vs. 25.6% (19.7−31.9), respectively (Fig. 1). The adjusted risk of major relapse was 24.9% (7.0−45.5) vs. 16.5% (12.3−21.9). In 105 PR3-ANCA patients, the corresponding relapse rate was 32.1% (11.9−54.1) vs. 26.4% (20.4−34.0) (Fig. 2). When restricted to patients with a doubling of the ANCA titer, the relapse rate was 36.2% (15.1−61.4) in 20 patient-periods vs. 25.3% (19.6−31.6) in 358 patient-periods. The difference in RMST between patients with and without an increased ANCA titer was -13.3 (-75.7−33.3) days, -14.2 (-80.8−33.9) days and -27.1 (-100.7−22.2) days for all patients, PR3-ANCA patients and patients with a doubling of the ANCA titer, respectively.

Conclusion: Despite using the same ELISA test consistently over time in a homogeneous population of GPA patients followed at a reference center, the predictive value of an increase in ANCA, a doubling of ANCA or an increase in PR3-ANCA alone is not sufficient to predict relapse at 18 months to consider escalating treatment on an individual basis.

Supporting image 1

Figure 1. Adjusted relapse rate for the cohort of GPA patients

Supporting image 2

Figure 2. Adjusted relapse rate for the cohort of GPA patients restricted to PR3-ANCA patients


Disclosures: X. Puéchal: None; M. Iudici: None; E. Perrodeau: None; C. Goulvestre: None; P. cohen: None; A. Régent: None; L. Mouthon: None; L. Guillevin: None; R. Porcher: None; B. Terrier: AstraZeneca, 2, GlaxoSmithKline, 2, Novartis, 2, Vifor Pharma, 2.

To cite this abstract in AMA style:

Puéchal X, Iudici M, Perrodeau E, Goulvestre C, cohen P, Régent A, Mouthon L, Guillevin L, Porcher R, Terrier B. Does Serial ANCA Testing Help Predict the Risk of Relapse in Granulomatosis with Polyangiitis? A Single-center Cohort Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/does-serial-anca-testing-help-predict-the-risk-of-relapse-in-granulomatosis-with-polyangiitis-a-single-center-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/does-serial-anca-testing-help-predict-the-risk-of-relapse-in-granulomatosis-with-polyangiitis-a-single-center-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology